Kohei Shitara, Aziz Zaanan, Sara Lonardi, Christelle de la Fouchardière, Clélia Coutzac, Eric Van Cutsem, Jeroen Dekervel, Lin Shen, Fabio André Franke, Yelena Y. Janjigian, Josep Tabernero, Chloe Spalding, Meredith Venerus, Fabricio Souza, Alessandro Ghiretti, Mahmut Gümüş, Filippo Pietrantonio. "Additional health-related quality of life (HRQoL) analysis from DESTINY-Gastric04 (DG-04), a randomized phase 3 study of trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) unresectable/metastatic gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA).." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.4111